Compare AVAV & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | ASND |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 12.2B |
| IPO Year | 2007 | 2015 |
| Metric | AVAV | ASND |
|---|---|---|
| Price | $278.56 | $205.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $352.21 | $256.27 |
| AVG Volume (30 Days) | ★ 779.9K | 640.2K |
| Earning Date | 12-09-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,085,820,000.00 | $758,592,045.00 |
| Revenue This Year | $148.47 | $99.74 |
| Revenue Next Year | $17.12 | $79.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 44.03 | ★ 97.46 |
| 52 Week Low | $102.25 | $118.03 |
| 52 Week High | $417.86 | $223.19 |
| Indicator | AVAV | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 49.03 |
| Support Level | $257.31 | $198.30 |
| Resistance Level | $292.75 | $218.50 |
| Average True Range (ATR) | 13.23 | 9.16 |
| MACD | 1.37 | -0.64 |
| Stochastic Oscillator | 54.90 | 28.05 |
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.